CJC-1295 / Ipamorelin

This is not one peptide but two, mixed in a single vial. CJC-1295 is a lab-made copy of growth hormone-releasing hormone (GHRH), the signal your brain normally sends to the pituitary gland to tell it to release growth hormone; the version sold in this blend usually carries a drug affinity complex (DAC), a chemical handle that lets it stick to albumin in your blood so it lingers for days instead of minutes. Ipamorelin is a five-amino-acid copy of ghrelin, the stomach hormone often called the hunger hormone, and it pushes the same pituitary cells through a second, separate door called the growth hormone secretagogue receptor. Neither one is growth hormone. Both are messages asking your own pituitary to release its own growth hormone, which is why they only work if that gland is still functioning.

• Raising your own growth hormone and insulin-like growth factor 1 (IGF-1) without injecting growth hormone itself
• Body composition goals: less fat, more lean mass, usually over months rather than weeks
• Sleep quality, since the largest natural growth hormone pulse happens in early deep sleep
• Recovery from hard training, soft-tissue injury and general wear
• Age-related decline in growth hormone output, which is a clinic-marketing use rather than an approved one

Think of your pituitary as a water tower with a release valve. CJC-1295 is a hand that rests on the valve lever for several days, raising the baseline trickle. Ipamorelin is a second hand that gives the lever a sharp squeeze for an hour or two. Push both at once and you get a bigger release than either hand manages alone, but nothing new is added to the tower, so what comes out still depends on what your own pituitary had in it.

1. First nightsUsers commonly report deeper or heavier sleep within the first few doses. This is reported experience, not a measured endpoint in any published trial of the blend.
2. Week 1-2The measurable change in this window is blood chemistry, not the mirror. In the human CJC-1295 work, IGF-1 rose within days of a single dose and stayed above baseline for a week or more.
3. Week 4-8Any change in body composition would show up here at the earliest. No published trial has measured body composition on this combination, so there is no timeline to quote.
4. Month 3+The cheatsheet cycle runs 12 to 16 weeks. There is no published human data on continuous use of either peptide for that long, so long-run effects are unknown rather than reassuring.
5. Post-cycleCJC-1295 has a half-life measured in days, so it clears slowly; ipamorelin clears in hours. Whether IGF-1 settles back to where it started has not been tracked in the literature for this blend.

• Injection site reactions: redness, itching or a small welt. Reported as mild in the CJC-1295 trials.
• Flushing and a brief feeling of warmth shortly after dosing, described for ipamorelin as uncommon.
• Water retention, puffy hands or feet, and joint or wrist aching. These are recognised consequences of pushing growth hormone and IGF-1 up rather than findings specific to these two peptides.
• Lightheadedness in the minutes after a dose, consistent with the vasodilatory reaction the FDA noted in its record of the withdrawn CJC-1295 compounding nomination.
• Higher fasting glucose and reduced insulin sensitivity are a known consequence of sustained growth hormone elevation. No published trial of this blend has measured it, which is a gap rather than a clean bill of health.
• In the ipamorelin postoperative ileus trial adverse events were no more frequent on drug than on placebo, but those were surgical patients and most of the events were surgical.

• You are pregnant, trying to conceive, or breastfeeding. There is no human safety data in pregnancy for either peptide.
• You have an active cancer or a personal history of one. Growth hormone and IGF-1 are growth signals, and deliberately raising them in that setting is not something the literature supports.
• You have diabetes, prediabetes, or active diabetic retinopathy, because sustained growth hormone elevation works against insulin sensitivity.
• You have an active or untreated pituitary lesion, or a diagnosis of acromegaly.
• You are a child or adolescent with open growth plates, unless an endocrinologist is directing it.
• You are an athlete subject to drug testing. Both compounds are named on the World Anti-Doping Agency Prohibited List at all times.
• You are not working with a physician who can order IGF-1, fasting glucose and HbA1c before and during use.

• Treating the blend as if it were growth hormone. It is a request to a gland, so if your pituitary output is genuinely low for a medical reason, this does not fix that.
• Dosing after a meal. Food, and carbohydrate in particular, blunts the growth hormone pulse, which is why the cheatsheet timing is before sleep on an empty stomach.
• Reconstituting with the wrong diluent or shaking the vial. Use bacteriostatic water, aim it at the glass wall rather than the powder, and swirl. Peptides in solution are fragile.
• Leaving the reconstituted vial out of the fridge, or in a door shelf that keeps warming up. Mixed peptide keeps for weeks refrigerated and loses potency quickly at room temperature.
• Assuming the DAC version needs daily dosing. The published human work on CJC-1295 with DAC used weekly or twice-weekly dosing because it lingers for days; a daily schedule for the DAC form has never been tested in a trial.
• Stacking it with an oral secretagogue or a second ghrelin mimetic on the assumption that hitting more receptors means more benefit, when the glucose cost of that stacking has not been characterised.